SLC5A2 and urinary tract infection: Studies (Matharu et al., 2021; Fitchett, 2019) have shown that SGLT2 inhibitors are associated with adverse drug reactions, such as genital mycotic infections (5% or higher) (Gorgojo-Martínez et al., 2024), urinary tract infections (3%–9%) (Gorgojo-Martínez et al., 2024), diabetic ketoacidosis (0.2%–0.6%) (Bi et al., 2024), and polyuria (2.7%) (Li CX.